Login to Your Account

FDA Advisers to Ponder Vision Loss Risks of Ovation's Sabril

By Donna Young

Tuesday, January 6, 2009
FDA drug reviewers said in briefing documents Monday that they were not confident that the risks of vision loss associated with Ovation Pharmaceuticals Inc.'s investigational antiepileptic drug Sabril (vigabatrin) could be mitigated sufficiently by a safety plan proposed by the Deerfield, Ill.-based firm. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription